CARLSBAD, Calif., July 31,
2022 /PRNewswire/ -- Active Motif Incorporated, a
company with the vision of bringing epigenetics more deeply
into precision medicine,
announced that it has non-exclusively
licensed its foundational patents in transposition
for use in CUT&Tag epigenetic assays to Diagenode
S.A., a Hologic company (NASDAQ: HOLX). The innovations
underlying these patents allow mechanistic, translational, and
clinical researchers to interrogate open chromatin with the goal of
gaining an increased understanding of biological processes.
Through the licensing arrangement, Diagenode gains access to Active
Motif's patents, which include US9938524, EP2783001, US10689643,
US11306307, EP 2999784, and other related
patent applications.
Details about Active Motif's proprietary
Cut&Tag-IT TM technology can be found at
www.activemotif.com/catalog/1318/cut-tag-it-kit
About Active Motif
Active Motif, Inc. is dedicated to
developing, manufacturing and delivering epigenetics-based research
tools to analyze nuclear function. Its customers include scientists
from academic and government institutions; biotechnology and
pharmaceutical companies. Active Motif operates globally through
its corporate headquarters in Carlsbad,
California and offices in Shanghai
China, Tokyo Japan and
Waterloo Belgium. Active Motif applies a multi-disciplinary
approach to create new and modify existing technologies to meet the
current and future needs of life science researchers.
Media Contact: Fritz Eibel,
Active Motif Incorporated, Feibel@activemotif.com
View original
content:https://www.prnewswire.com/news-releases/active-motif-incorporated-licenses-targeted-transposition-to-diagenode-sa-technology-301596546.html
SOURCE Active Motif